Current landscape of BRAF-V600E metastatic CRC management in Latin America: an expert Latin American panel’s recommendations

TL;DR

Latin American experts developed recommendations to improve BRAF-V600E metastatic colorectal cancer management due to current variability in testing and treatment.

Contribution

A set of expert recommendations for BRAF-V600E mCRC management in Latin America, addressing current limitations in diagnosis and treatment.

Findings

BRAF-V600E testing and treatment for metastatic CRC in Latin America remains variable.

Expert panel recommends multidisciplinary boards and tumor genotyping to improve care.

Panel provided first-line, second-line, and surgical recommendations for BRAF-V600E mCRC patients.

Abstract

Colorectal cancer is the second leading cause of cancer death in Latin America (LA) with a projected 65.4% increase by 2040. Up to 10% of metastatic CRC (mCRC) patients in LA had an activating BRAF mutation. In clinical trials, targeted therapies for BRAF-V600E mutated mCRC have improved patient outcomes. However, in LA, BRAF-V600E testing and treatment of positive patients remains variable. To address this need, the Americas Health Foundation convened a meeting of LA experts on BRAF-V600E mCRC to develop treatment recommendations. The expert panel addressed the current landscape of BRAF-V600E mCRC testing, diagnosis and treatment in the region and identified significant limitations. Local guidelines, multidisciplinary boards, and tumor genotyping are among the recommendations. The panel also made first-line, second-line and surgery recommendations for patients after diagnosis.

Figures